Clinical outcomes of transcarotid artery revascularization vs carotid endarterectomy from a large single-center experience

医学 颈动脉内膜切除术 冲程(发动机) 围手术期 血运重建 心力衰竭 内科学 心脏病学 心肌梗塞 外科 狭窄 机械工程 工程类
作者
Ali F. AbuRahma,Adrian Santini,Zachary AbuRahma,Andrew Lee,Christina Veith,Noah Dargy,Robert Cragon,Scott L. Dean,E Mattox
出处
期刊:Journal of Vascular Surgery [Elsevier BV]
标识
DOI:10.1016/j.jvs.2024.01.213
摘要

Abstract

Background

Transcarotid artery revascularization (TCAR) has been practiced as an alternative for both carotid endarterectomy (CEA) and transfemoral carotid artery stenting, specifically in high-risk patients. More recently, the Centers for Medicare and Medicaid Services expanded coverage for TCAR in standard surgical risk patients if done within the Society for Vascular Surgery Vascular Quality Initiative TCAR surveillance project. A few registry studies (primarily from the Society for Vascular Surgery Vascular Quality Initiative) compared the early and up to 1-year outcomes of TCAR vs CEA or transfemoral carotid artery stenting. There is no large single-center study that reported late clinical outcomes. The present study compares intermediate clinical outcomes of TCAR vs CEA.

Methods

This study retrospectively analyzed collected data from TCAR surveillance project patients enrolled in our institution and compare it with CEA patients done by the same providers at the same time period. The primary outcome was combined perioperative stroke/death and late stroke/death. Secondary outcomes included combined stroke, death, and myocardial infarction, cranial nerve injury (CNI), and bleeding. Propensity matching was done to analyze outcome. Kaplan-Meier analysis was used to estimate freedom from stroke, stroke/death, and ≥50% and ≥80% restenosis.

Results

We analyzed 646 procedures (637 patients) (404 CEA, 242 TCAR). There was no significant difference in the indications for carotid intervention. However, TCAR patients had more high-risk criteria, including hypertension, coronary artery disease, congestive heart failure, and renal failure. There was no significant differences between CEA vs TCAR in 30-day perioperative stroke (1% vs 2%), stroke/death rate (1% vs 3%; P = .0849), or major hematomas (2% vs 2%). The rate of CNI was significantly different (5% for CEA vs 1% for TCAR; P = .0138). At late follow-up (2 years), the rate of stroke was 1% vs 4% (P = .0273), stroke/death 8% vs 15% (P = .008), ≥80 % restenosis 0.5% vs 3% (P = .0139) for CEA patients vs TCAR patients, respectively. After matching 242 CEAs and 242 TCARs, the perioperative stroke rate was 1% for CEA vs 2% for TCAR (P = .5037), the stroke/death rate was 2% vs 3% (P = .2423), and the CNI rate was 3% vs 1% (P = .127). At late follow-up, rates of stroke were 1% for CEA vs 4% for TCAR (P = .0615) and stroke/death were 8% vs 15% (P = .0345). The rate of ≥80% restenosis was 0.9% for CEA vs 3% for TCAR (P = .099). The rates of freedom from stroke at 6, 12, 18, and 24 months for CEA vs TCAR were 99%, 99%, 99%, and 99% vs 97%, 95%, 93% and 93%, respectively (P = .0806); stroke/death were 94%, 90%, 87%, and 86% vs 93%, 87%, 76%, and 75%, respectively (P = .0529); and ≥80% restenosis were 100%, 99%, 98%, and 98% vs 97%, 95%, 93%, and 93%, respectively (P = .1132).

Conclusions

In a propensity-matched analysis, both CEA and TCAR have similar perioperative clinical outcomes. However, CEA was superior to TCAR for the rates of late stroke/death and had a somewhat lower rate of ≥80% restenosis at 2 years, but this difference was not statistically significant.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
意羡发布了新的文献求助20
1秒前
哟呵发布了新的文献求助10
1秒前
2秒前
2秒前
科研通AI6.4应助Greyson采纳,获得30
2秒前
2秒前
3秒前
3秒前
zwzh完成签到,获得积分10
3秒前
IMF完成签到,获得积分10
4秒前
meng发布了新的文献求助10
5秒前
沙心发布了新的文献求助10
5秒前
Newb1e发布了新的文献求助10
5秒前
江湖小妖完成签到,获得积分10
5秒前
5秒前
脏脏鲤发布了新的文献求助10
5秒前
llll完成签到,获得积分10
5秒前
没所谓完成签到,获得积分10
6秒前
6秒前
领导范儿应助Hannah采纳,获得10
6秒前
Hello应助开朗世立采纳,获得10
7秒前
赵新发布了新的文献求助10
7秒前
7秒前
8秒前
1266发布了新的文献求助10
8秒前
8秒前
CipherSage应助杨珠珠采纳,获得10
9秒前
十三十四十五完成签到,获得积分10
9秒前
animenz完成签到,获得积分10
9秒前
开朗战斗机完成签到,获得积分10
10秒前
10秒前
CipherSage应助EurosLiu采纳,获得10
10秒前
李科通发布了新的文献求助10
10秒前
Orange应助脏脏鲤采纳,获得10
10秒前
10秒前
Hello应助老仙翁采纳,获得10
11秒前
予安发布了新的文献求助10
11秒前
ycd发布了新的文献求助10
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Burger's Medicinal Chemistry, Drug Discovery and Development, Volumes 1 - 8, 8 Volume Set, 8th Edition 1800
Cronologia da história de Macau 1600
Netter collection Volume 9 Part I upper digestive tract及Part III Liver Biliary Pancreas 3rd 2024 的超高清PDF,大小约几百兆,不是几十兆版本的 1050
Current concept for improving treatment of prostate cancer based on combination of LH-RH agonists with other agents 1000
Research Handbook on the Law of the Sea 1000
Contemporary Debates in Epistemology (3rd Edition) 1000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 纳米技术 计算机科学 化学工程 生物化学 物理 复合材料 内科学 催化作用 物理化学 光电子学 细胞生物学 基因 电极 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6169009
求助须知:如何正确求助?哪些是违规求助? 7996579
关于积分的说明 16631669
捐赠科研通 5274122
什么是DOI,文献DOI怎么找? 2813630
邀请新用户注册赠送积分活动 1793373
关于科研通互助平台的介绍 1659311